LONDON — Conference organizers added a panel to discuss the experimental drug daraxonrasib to the schedule of a three-day pancreatic cancer conference held in London on July 13, 2026. The addition reflected heightened interest in the drug following recent clinical trial results that showed a significant survival benefit for patients with advanced pancreatic cancer.

The panel featured Talia Golan, an oncologist at Israel’s Sheba Medical Center, who described the findings as transformative. “It’s one of those moments,” Golan said during the discussion. She likened daraxonrasib’s clinical trial performance to historic milestones in cancer treatment, such as the introduction of the first checkpoint inhibitors.

In the study underpinning the discussion, patients who received daraxonrasib lived nearly twice as long as those treated with standard chemotherapy. The trial included 500 participants, all of whom had advanced pancreatic cancer. The results were first presented publicly at a medical conference in Chicago in May 2026, generating initial buzz in the oncology community before the London session.

Daraxonrasib is developed by Revolution Medicines, a biopharmaceutical company focused on targeting oncogenic drivers in solid tumors. Despite the encouraging data, the drug has not yet undergone regulatory review by any health authority, meaning it remains unavailable outside clinical trials. Clinicians at the conference noted that while the survival benefit was compelling, daraxonrasib may carry side effects, and physicians would need to clearly explain its limitations to patients if it eventually reaches the market.

Discussion at the panel also addressed broader implications of the drug’s potential launch. Experts acknowledged that daraxonrasib’s expected high cost could create challenges related to affordability and lead to uneven access across healthcare systems. These concerns reflect a recurring pattern in oncology, where breakthrough therapies often arrive with price tags that strain public and private payers alike.

Why It Matters

Pancreatic cancer remains one of the most difficult malignancies to treat, with a five-year survival rate below 10%. The arrival of a therapy that nearly doubles survival time in a 500-patient trial represents a rare advance in a field with few recent therapeutic breakthroughs. While daraxonrasib is not yet approved, its performance echoes the significance of earlier paradigm-shifting treatments like checkpoint inhibitors, which reshaped care in other cancers.

The drug targets oncogenic KRAS, a long-considered “undruggable” protein. Research dating back to a 2017 study published in Nature—titled “Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer”—helped lay groundwork for current approaches. If regulatory approval follows, daraxonrasib could become a cornerstone of treatment, though access and cost barriers may limit its reach.